Cancer cure for 32 cancer types: results from the EUROCARE-5 study

Luigino Dal Maso; Chiara Panato; Andrea Tavilla; Stefano Guzzinati; Diego Serraino; Sandra Mallone; Laura Botta; Olayidé Boussari; Riccardo Capocaccia; Marc Colonna; Emanuele Crocetti; Agnes Dumas; Tadek Dyba; Silvia Franceschi; Gemma Gatta; Anna Gigli; Francesco Giusti; Valerie Jooste; Pamela Minicozzi; Luciana Neamtiu; Gaëlle Romain; Manuel Zorzi; Roberta De Angelis; Silvia Francisci; EUROCARE-5 Working Group; Rosa Filiberti

doi:10.1093/ije/dyaa128

Cancer cure for 32 cancer types: results from the EUROCARE-5 study

Luigino Dal Maso, Chiara Panato, Andrea Tavilla, Stefano Guzzinati, Diego Serraino, Sandra Mallone, Laura Botta, Olayidé Boussari, Riccardo Capocaccia, Marc Colonna, Emanuele Crocetti, Agnes Dumas, Tadek Dyba, Silvia Franceschi, Gemma Gatta, Anna Gigli, Francesco Giusti, Valerie Jooste, Pamela Minicozzi, Luciana NeamtiuGaëlle Romain, Manuel Zorzi, Roberta De Angelis, Silvia Francisci, EUROCARE-5 Working Group, Rosa Filiberti

Research output: Contribution to journal › Article › peer-review

Abstract

BACKGROUND: Few studies have estimated the probability of being cured for cancer patients. This study aims to estimate population-based indicators of cancer cure in Europe by type, sex, age and period. METHODS: 7.2 million cancer patients (42 population-based cancer registries in 17 European countries) diagnosed at ages 15-74 years in 1990-2007 with follow-up to 2008 were selected from the EUROCARE-5 dataset. Mixture-cure models were used to estimate: (i) life expectancy of fatal cases (LEF); (ii) cure fraction (CF) as proportion of patients with same death rates as the general population; (iii) time to cure (TTC) as time to reach 5-year conditional relative survival (CRS) >95%. RESULTS: LEF ranged from 10 years for chronic lymphocytic leukaemia patients to 5 years for women with breast cancer. The CF was 94% for testis, 87% for thyroid cancer in women and 70% in men, 86% for skin melanoma in women and 76% in men, 66% for breast, 63% for prostate and

Original language	English
Pages (from-to)	1517-1525
Number of pages	9
Journal	International Journal of Epidemiology
Volume	49
Issue number	5
DOIs	https://doi.org/10.1093/ije/dyaa128
Publication status	Published - 2020

Keywords

IMP

Access to Document

10.1093/ije/dyaa128

http://www.ncbi.nlm.nih.gov/pubmed/32984907

Fingerprint Dive into the research topics of 'Cancer cure for 32 cancer types: results from the EUROCARE-5 study'. Together they form a unique fingerprint.

Cite this

Dal Maso, L., Panato, C., Tavilla, A., Guzzinati, S., Serraino, D., Mallone, S., Botta, L., Boussari, O., Capocaccia, R., Colonna, M., Crocetti, E., Dumas, A., Dyba, T., Franceschi, S., Gatta, G., Gigli, A., Giusti, F., Jooste, V., Minicozzi, P., ... Filiberti, R. (2020). Cancer cure for 32 cancer types: results from the EUROCARE-5 study. International Journal of Epidemiology, 49(5), 1517-1525. https://doi.org/10.1093/ije/dyaa128

Cancer cure for 32 cancer types: results from the EUROCARE-5 study. / Dal Maso, Luigino; Panato, Chiara; Tavilla, Andrea; Guzzinati, Stefano; Serraino, Diego; Mallone, Sandra; Botta, Laura; Boussari, Olayidé; Capocaccia, Riccardo; Colonna, Marc; Crocetti, Emanuele; Dumas, Agnes; Dyba, Tadek; Franceschi, Silvia ; Gatta, Gemma; Gigli, Anna; Giusti, Francesco; Jooste, Valerie; Minicozzi, Pamela; Neamtiu, Luciana; Romain, Gaëlle; Zorzi, Manuel; De Angelis, Roberta ; Francisci, Silvia; Group, EUROCARE-5 Working; Filiberti, Rosa.

In: International Journal of Epidemiology, Vol. 49, No. 5, 2020, p. 1517-1525.

Research output: Contribution to journal › Article › peer-review

Dal Maso, L, Panato, C, Tavilla, A, Guzzinati, S, Serraino, D, Mallone, S, Botta, L, Boussari, O, Capocaccia, R, Colonna, M, Crocetti, E, Dumas, A, Dyba, T, Franceschi, S , Gatta, G, Gigli, A, Giusti, F, Jooste, V, Minicozzi, P, Neamtiu, L, Romain, G, Zorzi, M, De Angelis, R , Francisci, S, Group, EUROCAREW & Filiberti, R 2020, 'Cancer cure for 32 cancer types: results from the EUROCARE-5 study', International Journal of Epidemiology, vol. 49, no. 5, pp. 1517-1525. https://doi.org/10.1093/ije/dyaa128

Dal Maso, Luigino ; Panato, Chiara ; Tavilla, Andrea ; Guzzinati, Stefano ; Serraino, Diego ; Mallone, Sandra ; Botta, Laura ; Boussari, Olayidé ; Capocaccia, Riccardo ; Colonna, Marc ; Crocetti, Emanuele ; Dumas, Agnes ; Dyba, Tadek ; Franceschi, Silvia ; Gatta, Gemma ; Gigli, Anna ; Giusti, Francesco ; Jooste, Valerie ; Minicozzi, Pamela ; Neamtiu, Luciana ; Romain, Gaëlle ; Zorzi, Manuel ; De Angelis, Roberta ; Francisci, Silvia ; Group, EUROCARE-5 Working ; Filiberti, Rosa. / Cancer cure for 32 cancer types: results from the EUROCARE-5 study. In: International Journal of Epidemiology. 2020 ; Vol. 49, No. 5. pp. 1517-1525.

@article{117b1cdadf0d490daae60418b0a9525b,

title = "Cancer cure for 32 cancer types: results from the EUROCARE-5 study",

abstract = "BACKGROUND: Few studies have estimated the probability of being cured for cancer patients. This study aims to estimate population-based indicators of cancer cure in Europe by type, sex, age and period. METHODS: 7.2 million cancer patients (42 population-based cancer registries in 17 European countries) diagnosed at ages 15-74 years in 1990-2007 with follow-up to 2008 were selected from the EUROCARE-5 dataset. Mixture-cure models were used to estimate: (i) life expectancy of fatal cases (LEF); (ii) cure fraction (CF) as proportion of patients with same death rates as the general population; (iii) time to cure (TTC) as time to reach 5-year conditional relative survival (CRS) >95%. RESULTS: LEF ranged from 10 years for chronic lymphocytic leukaemia patients to 5 years for women with breast cancer. The CF was 94% for testis, 87% for thyroid cancer in women and 70% in men, 86% for skin melanoma in women and 76% in men, 66% for breast, 63% for prostate and ",

keywords = "IMP",

author = "{Dal Maso}, Luigino and Chiara Panato and Andrea Tavilla and Stefano Guzzinati and Diego Serraino and Sandra Mallone and Laura Botta and Olayid{\'e} Boussari and Riccardo Capocaccia and Marc Colonna and Emanuele Crocetti and Agnes Dumas and Tadek Dyba and Silvia Franceschi and Gemma Gatta and Anna Gigli and Francesco Giusti and Valerie Jooste and Pamela Minicozzi and Luciana Neamtiu and Ga{\"e}lle Romain and Manuel Zorzi and {De Angelis}, Roberta and Silvia Francisci and Group, {EUROCARE-5 Working} and Rosa Filiberti",

year = "2020",

doi = "10.1093/ije/dyaa128",

language = "English",

volume = "49",

pages = "1517--1525",

journal = "International Journal of Epidemiology",

issn = "0300-5771",

publisher = "Oxford University Press",

number = "5",

}

TY - JOUR

T1 - Cancer cure for 32 cancer types: results from the EUROCARE-5 study

AU - Dal Maso, Luigino

AU - Panato, Chiara

AU - Tavilla, Andrea

AU - Guzzinati, Stefano

AU - Serraino, Diego

AU - Mallone, Sandra

AU - Botta, Laura

AU - Boussari, Olayidé

AU - Capocaccia, Riccardo

AU - Colonna, Marc

AU - Crocetti, Emanuele

AU - Dumas, Agnes

AU - Dyba, Tadek

AU - Franceschi, Silvia

AU - Gatta, Gemma

AU - Gigli, Anna

AU - Giusti, Francesco

AU - Jooste, Valerie

AU - Minicozzi, Pamela

AU - Neamtiu, Luciana

AU - Romain, Gaëlle

AU - Zorzi, Manuel

AU - De Angelis, Roberta

AU - Francisci, Silvia

AU - Group, EUROCARE-5 Working

AU - Filiberti, Rosa

PY - 2020

Y1 - 2020

N2 - BACKGROUND: Few studies have estimated the probability of being cured for cancer patients. This study aims to estimate population-based indicators of cancer cure in Europe by type, sex, age and period. METHODS: 7.2 million cancer patients (42 population-based cancer registries in 17 European countries) diagnosed at ages 15-74 years in 1990-2007 with follow-up to 2008 were selected from the EUROCARE-5 dataset. Mixture-cure models were used to estimate: (i) life expectancy of fatal cases (LEF); (ii) cure fraction (CF) as proportion of patients with same death rates as the general population; (iii) time to cure (TTC) as time to reach 5-year conditional relative survival (CRS) >95%. RESULTS: LEF ranged from 10 years for chronic lymphocytic leukaemia patients to 5 years for women with breast cancer. The CF was 94% for testis, 87% for thyroid cancer in women and 70% in men, 86% for skin melanoma in women and 76% in men, 66% for breast, 63% for prostate and

AB - BACKGROUND: Few studies have estimated the probability of being cured for cancer patients. This study aims to estimate population-based indicators of cancer cure in Europe by type, sex, age and period. METHODS: 7.2 million cancer patients (42 population-based cancer registries in 17 European countries) diagnosed at ages 15-74 years in 1990-2007 with follow-up to 2008 were selected from the EUROCARE-5 dataset. Mixture-cure models were used to estimate: (i) life expectancy of fatal cases (LEF); (ii) cure fraction (CF) as proportion of patients with same death rates as the general population; (iii) time to cure (TTC) as time to reach 5-year conditional relative survival (CRS) >95%. RESULTS: LEF ranged from 10 years for chronic lymphocytic leukaemia patients to 5 years for women with breast cancer. The CF was 94% for testis, 87% for thyroid cancer in women and 70% in men, 86% for skin melanoma in women and 76% in men, 66% for breast, 63% for prostate and

KW - IMP

U2 - 10.1093/ije/dyaa128

DO - 10.1093/ije/dyaa128

M3 - Article

VL - 49

SP - 1517

EP - 1525

JO - International Journal of Epidemiology

JF - International Journal of Epidemiology

SN - 0300-5771

IS - 5

ER -